Mission Statement, Vision, & Core Values (2026) of Tianjin Ringpu Bio-Technology Co.,Ltd.

Tianjin Ringpu Bio-Technology Co., Ltd. (listed as 300119.SZ) has grown from its 1998 founding into a major force in veterinary biopharmaceuticals-employing roughly 2,900 people by late 2025 and generating 3.07 billion yuan in revenue in 2024 (a 13.32% year‑on‑year rise)-and this chapter peels back how that commercial momentum aligns with a mission to expand affordable, high‑quality biotech solutions, a vision to lead in all‑natural performance materials, and core values that prioritize innovation, sustainability and social impact; read on to see how sustained R&D investment (about 10% of 2022 revenue), a reported 15% reduction in carbon emissions over three years, a 50 million yuan donation to healthcare in 2022, and an enterprise value of 10.15 billion yuan (Dec 2025) shape Ringpu's strategic choices across products from anthelmintics and vaccines to functional additives and disinfectants for poultry, livestock and companion animals.

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Intro

• Founded: 1998
• Employees (late 2025): ~2,900
• Primary markets: poultry, livestock, companion animals
• Main products: anthelmintics, vaccines (including pet vaccines), antibiotics, antivirals, disinfectants

• Advance animal health through science-driven R&D of safe, effective veterinary medicines and biologicals.
• Deliver reliable, cost-effective solutions that improve livestock productivity, animal welfare and companion animal care.
• Support sustainable animal agriculture and public health by reducing disease burden and antimicrobial risks.

• Become a leading global animal health innovator originating from China, recognized for breakthrough vaccines, biologics and functional additives.
• Expand international footprint while maintaining high standards of quality, biosafety and regulatory compliance.
• Drive industry transformation through digitalized R&D, precision manufacturing and integrated supply chain capability.

• Scientific integrity - rigorous research, evidence-based product claims, and continuous validation.
• Quality and safety - adherence to GMP, cold-chain controls for biologics, and strict QC across production lines.
• Customer focus - responsiveness to veterinarians, farmers and pet owners; tailored solutions across species and production systems.
• Collaboration - partnerships with academic institutes, CROs and distribution networks to accelerate product development and market access.
• Sustainability - efficient resource use, reduced environmental impact from manufacturing, and responsible antimicrobial stewardship.
• Employee development - investment in talent (R&D, regulatory, production) to support innovation and operational excellence.

• R&D investment in vaccines and biologics to capture higher-margin product mix and reduce reliance on small‑molecule APIs.
• Scale manufacturing capacity and quality systems to support export-ready dossiers and international registrations.
• Commercial expansion across China's large-scale farming clusters and into selective overseas markets leveraging regulatory approvals.
• Operational efficiency programs to sustain EBITDA margins amid revenue growth (3.07 billion yuan in 2024, +13.32% YoY).

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Overview

• Mission: Become a leader in biopharmaceutical and bioengineering technologies, improving quality of life via biotechnology innovation.
• Vision: Deliver high-quality, affordable healthcare solutions to global markets, expanding access to essential medicines and biologics.
• Social responsibility: Support underserved regions through targeted healthcare funding and community programs.

• R&D focus: Sustained allocation (~10% of revenue in 2022) to drug discovery, process development, and bioengineering scale-up to accelerate pipeline advancement and manufacturing efficiency.
• Quality & compliance: Robust quality control overseen by a central department to maintain adherence to international GMP and regulatory frameworks, ensuring product reliability for domestic and export markets.
• Environmental stewardship: Implementation of energy- and resource-efficiency measures that achieved a 15% reduction in carbon emissions across operations over three years, integrated into procurement and facility upgrades.
• Community impact: Direct financial support (50 million yuan in 2022) for public-health programs in underserved regions, complementing product-access strategies and partnerships.

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Mission Statement

• Deliver consistent product quality that meets regulatory and industry performance benchmarks (e.g., pharmaceutical excipient standards, food-grade certifications).
• Scale manufacturing with environmental stewardship-reducing energy and water intensity per tonne of product year-on-year.
• Invest in customer-driven innovation to shorten application development cycles and expand end‑use adoption globally.

• Global technical leadership: expand overseas technical service centers and partnerships to support formulation adoption and regulatory filings.
• Product relevance: accelerate product portfolio renewal-targeting >20% revenue from products launched within the last 5 years.
• Quality-first manufacturing: maintain or improve demonstrated batch release pass rates above 99% and lower customer complaints per million units sold.
• Sustainability alignment: increase proportion of raw materials from certified sustainable sources and pursue lower carbon intensity targets.

• Innovation pipeline: sustained funding for formulation science, process intensification and functionalization of natural polymers.
• Quality systems: continued compliance with GMP, ISO and customer-specific audit outcomes to enable pharmaceutical and food-grade supply.
• Manufacturing scale & flexibility: capacity expansions and modular facilities to lower unit costs and improve lead times.
• Customer-centric commercialization: technical application labs and co-development programs to accelerate adoption.
• Sustainability & traceability: supplier audits, lifecycle assessments, and measurable reductions in water/energy per kg produced.

Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ) - Vision Statement

• Focus on continuous innovation: advance pipeline products, expand bioprocessing capabilities, and accelerate technology transfer.
• Commitment to quality: maintain rigorous GMP standards, third-party quality certifications, and top-tier product safety metrics.
• Sustainable growth: minimize environmental impact through energy efficiency and cleaner production methods.
• Social accountability: deploy resources to improve healthcare access and community well-being in underserved regions.

Key strategic imperatives align with measurable targets and past accomplishments, reflecting how the company's vision translates into concrete action and results.

Core Values Driving the Vision

• Innovation: sustained R&D funding (¥120M in 2023) and strategic partnerships to accelerate drug discovery and bioprocess optimization.
• Growth & Re-innovation: iterative product lifecycle management and expansion into new therapeutic areas to sustain top-line growth (¥1.2B revenue in 2023).
• Quality: adherence to GMP and quality systems, supporting consistent regulatory approvals and market access.
• Sustainability: operational measures leading to a 15% reduction in carbon emissions across manufacturing and logistics over three years.
• Social Responsibility: targeted contributions, including a ¥50M donation in 2022 to improve healthcare in underserved regions, and ongoing community health programs.

These values inform capital allocation, R&D prioritization, manufacturing upgrades, and stakeholder engagement, balancing commercial performance with environmental and social commitments. Further financial context and investor-oriented analysis are available here: Breaking Down Tianjin Ringpu Bio-Technology Co.,Ltd. Financial Health: Key Insights for Investors